Company Analysis
Sign in

ALX Oncology Holdings Inc. (ALXO)

Nasdaq: ALXO · Pharmaceutical Preparations · South San Francisco, CA · filing with the SEC since 2020
Full chart Alerts Compare
Grade3.3
◀ Past 3.7● Present 3.4▶ Future 2.9
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

13 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to ALX Oncology Holdings Inc.’s names, not what it holds today.

Patents granted
13
13 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 3 in 2024 and 2 in 2023
Applications published
31
3 of them in 2025
Names they are printed under
2
a subsidiary
By yearGrantedApplications published
'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals9
Biotechnology2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
ALX Oncology Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
30 published
ALX Oncology Inc. a subsidiary
US, as the owner printed on each patent
13 granted
1 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Sep 2, 202512,404,340Antibodies against signal-regulatory protein alpha and methods of usePharmaceuticalsALX Oncology Inc.
Jul 1, 202512,343,377Combination therapies comprising a hypomethylation agent for treating cancerPharmaceuticalsALX Oncology Inc.
Sep 24, 202412,098,214Combination therapies for treating cancerPharmaceuticalsALX Oncology Inc.
Mar 26, 202411,939,393Antibodies against signal-regulatory protein alpha and methods of usePharmaceuticalsALX Oncology Inc.
Mar 26, 202411,939,385Activatable antibodies and methods of use thereofBiotechnologyALX Oncology Inc.
May 2, 202311,639,376Constructs having a SIRP-α domain or variant thereofPharmaceuticalsALX Oncology Inc.
Mar 28, 202311,613,564Methods of treating cancerBiotechnologyALX Oncology Inc.
Aug 2, 202211,401,338Antibodies against signal-regulatory protein alpha and methods of usePharmaceuticalsALX Oncology Inc.
Apr 5, 202211,292,850Antibodies against signal-regulatory protein α and methods of usePharmaceuticalsALX Oncology Inc.
Feb 8, 202211,242,404Antibodies against signal-regulatory protein alpha and methods of usePharmaceuticalsALX Oncology Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 4, 20252025/0368712METHODS OF TREATING CANCERPharmaceuticalsALX Oncology Inc.
Mar 27, 20252025/0101032EXATECAN DERIVATIVES AND ANTIBODY-DRUG CONJUGATES THEREOFPharmaceuticalsALX Oncology Inc.
Jan 9, 20252025/0011737SIRP-ALPHA VARIANT CONSTRUCTS AND USES THEREOFPharmaceuticalsALX Oncology Inc.
Oct 17, 20242024/0343778CONSTRUCTS HAVING A SIRP-ALPHA DOMAIN OR VARIANT THEREOFPharmaceuticalsALX Oncology Inc.
Oct 3, 20242024/0327527ACTIVATABLE ANTIBODIES AND METHODS OF USE THEREOFBiotechnologyALX Oncology Inc.
Jul 11, 20242024/0228574METHODS OF TREATING CANCERPharmaceuticalsALX Oncology Inc.
Apr 25, 20242024/0132567METHODS OF TREATING CANCERPharmaceuticalsALX Oncology Inc.
Mar 7, 20242024/0075101COMBINATION THERAPIES FOR TREATING CANCERPharmaceuticalsALX Oncology Inc.
Jan 11, 20242024/0010701COMBINATION THERAPIES FOR TREATING UROTHELIAL CARCINOMAPharmaceuticalsALX Oncology Inc.
Oct 26, 20232023/0340433SIRP-ALPHA VARIANT CONSTRUCTS AND USES THEREOFPharmaceuticalsALX Oncology Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 8 · Biotechnology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton ALXO · research, not advice